Why the study?
Larger clinical trials across multiple patient groups are needed to understand the clinical role of FXI/XIa inhibitors.
Do Factor XI/XIa inhibitors prevent pathologic thromboembolic events while preserving hemostasis and minimizing bleeding risk compared to standard anticoagulants or placebo across cardiovascular and thrombotic conditions?
Do Factor XI/XIa inhibitors prevent pathologic thromboembolic events while preserving hemostasis and minimizing bleeding risk compared to standard anticoagulants or placebo across cardiovascular and thrombotic conditions?
Factor XI/XIa inhibitors represent a promising novel class of anticoagulants that may uncouple thrombosis prevention from bleeding risk, with encouraging Phase 2 safety and VTE prophylaxis efficacy warranting large Phase 3 outcome trials.
May support Phase 3 trials of FXI/XIa inhibitors for VTE prevention; leaves open changes to clinical practice pending confirmatory outcome data.
Factor XI/XIa represents a potential target for improved precision in anticoagulation, because it is involved primarily in thrombus formation and plays a much smaller role in clotting and hemostasis. This suggests that inhibition of FXI/XIa could prevent pathologic thrombi from forming, but largely preserve a patient’s ability to clot in response to bleeding/trauma. This theory is supported by observational data showing that patients with congenital FXI deficiency have lower rates of embolic events without an increase in spontaneous bleeding. Small Phase 2 trials of FXI/XIa inhibitors have offered encouraging data with regards to bleeding and safety, and evidence of efficacy for prevention of venous thromboembolism. However, larger clinical trials across multiple patient groups are needed for this emerging class of anticoagulants in order to understand their possible role in clinical use. Here we review the potential clinical indications for FXI/XIa inhibitors, data available to date, and consider future trials.
No takes yet. Share an insight, caveat, or question.
Harrington et al. (2023) conducted a review in Thromboembolic conditions including venous thromboembolism prophylaxis, atrial fibrillation, myocardial infarction, and non-cardioembolic stroke. Factor XI/XIa inhibitors (milvexian, asundexian, abelacimab, osocimab, FXI-ASO) vs. Standard anticoagulation (enoxaparin, apixaban, rivaroxaban) or placebo was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: